Work

Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps3161

Authors: Pasi A. Janne, Joseph Mostillo, Pomy Shrestha, Ruoyang Zhang, Pang-Dian Fan, Frédérique Cantero

Institutions: Dana-Farber Cancer Institute, Daiichi Sankyo (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281751437

Cites:

Cited by: 9

Related to: 10